Overall, 20 of the 25 firms in the index saw their share prices grow in May, including seven whose stocks rose more than 20 percent compared to April.
The in-vitro diagnostic contract research organization is targeting hospitals with its new reference testing services.
The company reported that it signed agreements for 345 instruments, while revenue-generating placements totaled 89 across the US and European regions.
Seventeen of the 25 companies in the 360Dx Index saw their shares decline last month. Invitae paced the decliners, while GenMark led the gainers.
The firm will use a portion of the proceeds for general corporate purposes and to fund its commercialization efforts
The company reported that it signed agreements for 337 instruments , while revenue-generating placements totaled 78 across the US, European, and Middle East regions.
At the JPM Healthcare Conference on Wednesday, its CEO also said that lower-than-anticipated revenues in Q4 2017 were due to a longer-than-expected sales cycle.
The firm expects full-year revenues of $4.2 million compared to revenues of $39,000 in 2016.
Drug-breakpoint updates should provide a clearer regulatory path for AST system makers but it's only one step in the fight against antimicrobial resistance, said Romney Humphries of Accelerate Diagnostics.
The stock prices of 17 of the 25 firms in the 360Dx Index fell month over month with Enzo Biochem and Bio-Rad leading decliners.